Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Automated Multiplex Diagnostics System Enables Rapid Detection of Multiple Pathogens

By LabMedica International staff writers
Posted on 04 Dec 2024

Each year, the World Health Organization (WHO) releases its Compendium of Innovative Health Technologies for Low-resource Settings, which highlights commercially available solutions and prototypes designed to tackle the challenges faced by low- and middle-income countries in accessing effective, safe, and affordable health technologies. More...

These technologies are crucial in addressing infectious diseases and the growing burden of non-communicable diseases such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. The WHO’s 2024 Compendium has recommended a novel automated multiplex diagnostics system as an innovative technology with significant potential to support health systems in these regions.

Developed at Hong Kong Baptist University (HKBU, Kowloon Tong, Hong Kong), the Automated Multiplex Diagnostics System recommended by the WHO’s 2024 Compendium offers a fully automated solution for conventional laboratory-based PCR (polymerase chain reaction) processes. The system consists of three integrated components: an analytical machine, a microfluidic reagent cartridge, and software. Its unique design enables the detection of 42 respiratory pathogens—28 viruses, 11 bacteria, and 3 fungi—in less than 1.5 hours, without requiring a resource-heavy laboratory, specialized equipment, or highly trained technicians, while ensuring high sensitivity and specificity.

In addition to its impressive performance, the system also offers several advantages in terms of cost-effectiveness, reduced turnaround time, and the ability to analyze multiple targets simultaneously. The system, created by a research team led by Professor Terence Lau from HKBU, is featured as one of 21 highlighted health technologies in the WHO’s 2024 Compendium under the prototype category. The concept for a fully automated, rapid, accurate, and affordable multiplex pathogen detection device was conceived in 2015, and its capabilities were expanded to support the detection of 40 targets, including SARS-CoV-2, in response to the urgent demand for decentralized diagnostics during the COVID-19 pandemic in 2020.

"The System can identify infectious diseases and even non-communicable diseases, and is suitable for other non-medical applications," said Professor Lau. "With this System, we will be able to provide a comprehensive solution that can eventually promote equitable access and decentralized testing for an effective and high-quality healthcare system which WHO emphasizes."

Related Links:
HKBU 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.